The Result of Combined Modelity Treatment for Limited Stage Small Cell Lung Cancer

• 발행기관: 대한방사선종양학회
• 저자명: 김재철(Jae Cheol Kim) 장양숙(Yang Suk Jang) 류삼열(Samuel Ryu) 박인규(In Kyu Park)
• 간행물 정보: 『대한방사선종양학회지』제7권 제2호, 205~211쪽, 전체 7쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 1989.12.30

국문 초록

1984년 7월부터 1988년 9월까지 경북대학교병원 치료방사선과에서 소세포 폐암으로 진단되어 복합화학요법 및 방사선 병용치료를 받은 27명을 대상으로 치료성적을 분석하였다. 완전관해율은 70%, 부분관해율은 22%, 무반응은 8%였다. 여자, 수행상태 HO, 방사선량 4500cGy 이상, 화학요법 4회 이상, 그리고 혈청 enolase 수치 30ng/ml 이하 등에서 완전관해율이 높게 나타났으나 통계적 의의는 없었다. 중앙생존기간은 10개월이었고 1년생존율과 2년생존율은 각각 40.7% 및 12.2%였다. 생존율을 높이는 인자로는 수행상태 HO(p<0.05), 완전관해(p<0.05), 화학요법 4회 이상 (p<0.05), 방사선량 4500cGy이상 등으로 나타났으며, 성별과 예방적 전뇌조사는 영향을 미치지 않았다.

영문 초록

From July 1984 to September 1988, 27 patients with limited stage small cell lung cancer were treated with combined modality (combination chemotherapy plus radiotherapy) at the Department of Therapeutic Radiology in Kyungpook National Unviersity Hospital. Of the 27 patients, 19 (70%) achieved a complete response, 6 (22%) a partial response, and 2 (8%) no response. Female. performance status HO, serum enolase level below 30 ng/ml, radiation dose over 4500 cGy, and 4 or more cycles of chemotherapy had a favorable effect on the rates of complete response, although there were no statistical differences according to the variables. Median survival time was 10 months and overall 1-and 2-year survival rates were 40.7% and 12.2%, respectively. Complete response (p<0.05), performance status HO (p<0.05), 4 or mote cycles of chemotherapy (p<0.05), and radiation dose over 4500 cGy had a significantly favorable effect on 2-year survival rate. Prophylactic cranial irradiation or sex had no effect on survival. The results of this study suggest that radiation treatment should be combined with combination chemotherapy in the therapeutic strategy of SCLC of limited stage.

키워드

Lung cancer Small cell Carcinoma Limited stage Combined modality therapy